Full Press Release Details
Allarity Therapeutics Reports First Quarter
Financial Results and Highlights,
including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and
Significant Improvement
in Cash and Equity Balances
- Phase 2 Trial of Stenoparib
Concluded Early due to Clear Clinical Benefits Achieved
- On Track to Regain Compliance with All Nasdaq Listing Requirements
No Variable Priced Securities are Outstanding,
Warrant Overhang Near Elimination
Allarity Withdraws its Form S-1
Establishes Equity of $15 Million
Cash Balance of $14 Million
Boston (May 14, 2024)-Allarity Therapeutics, Inc. ("Allarity"
or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer
treatments, today reported financial results and provided an update on recent operational highlights for the first quarter that ended
"The start of 2024 has been a pivotal period for Allarity Therapeutics,
marked by significant achievements across financial, regulatory, and clinical areas," remarked Thomas Jensen, CEO of Allarity Therapeutics.
"Our trials of stenoparib in advanced, recurrent ovarian cancer have yielded encouraging proof of concept data, which further boosted
our optimism for the future of this novel PARP inhibitor. Additionally, we've seen several developments that we believe may strengthen
our investment case. Our capital structure has been simplified, and we have raised new equity, so we are now on track to fully comply
with Nasdaq's listing requirements and find ourselves in a better position to steer clear of less favorable future financing arrangements.
Reflecting this new strengthened financial position, we have requested the SEC to withdraw our Form S-1 filed last October. With a strategic
focus now solely on stenoparib, we can use all our managerial resources to advance this promising asset toward regulatory approval."
Allarity Therapeutics, Inc. | 24
School Street, 2nd Floor | Boston, MA | U.S.A. | NASDAQ:
ALLR | www.allarity.com
First Quarter 2024 and Recent Operational Highlights
Allarity Therapeutics, Inc. | 24
School Street, 2nd Floor | Boston, MA | U.S.A. | NASDAQ:
ALLR | www.allarity.com
First Quarter 2024 Operating Results
R&D Expenses: Research and Development (R&D) expenses
for the quarter ended March 31, 2024, were $2.2 million, compared to $1.4 million for the quarter ended March 31, 2023. R&D costs
were approximately $743 thousand higher in 2024 than in 2023, primarily because of increased manufacturing costs of $524 thousand and
because of an extension fee payment of $150 thousand we paid to Eisai Co., Ltd. for our license agreement on stenoparib.
G&A Expenses: General and Administrative (G&A) expenses
for the quarter ended March 31, 2024, were $2.1 million, compared to $2.2 million for the quarter ended March 31, 2023. This decrease
in G&A expenses was primarily due to reduced insurance and professional fee expenses.
Net Loss from Operations: Net Loss from Operations for the quarter
ended March 31, 2024, was $4.2 million, compared to $3.7 million for the quarter ended March 31, 2023.
Net Loss: Net loss was $3.8 million for the quarter ended March
31, 2024, compared to $3.4 million for the quarter ended March 31, 2023.
About the Drug Response Predictor - DRP Companion Diagnostic
Allarity uses its drug-specific DRP to select those patients who,
by the gene expression signature of their cancer, are found to have a high likelihood of benefiting from a specific drug. By screening
patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit
rate may be significantly increased. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including
transcriptomic information from cell lines combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based
on messenger RNA expression profiles from patient biopsies. The DRP platform has proven its ability to provide a statistically significant
prediction of the clinical outcome from drug treatment in cancer patients dozens of clinical studies (both retrospective and prospective).
The DRP platform, which can be used in all cancer types and is patented for more than 70 anti-cancer drugs, has been extensively published
in the peer-reviewed literature.
About Allarity Therapeutics
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical
company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/Tankyrase
inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing
phase 2 clinical trial, NCT03878849. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing
significant unmet medical needs in cancer treatment. For more information, visit www.allarity.com.
Follow Allarity on Social Media
Therapeutics, Inc. | 24 School Street, 2nd Floor | Boston,
MA | U.S.A. | NASDAQ: ALLR | www.allarity.com
Forward-Looking Statements
This press release contains "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current
expectations or forecasts of future events. The words "anticipates," "believe," "continue," "could,"
"estimate," "expect," "intends," "may," "might," "plan," "possible,"
"potential," "predicts," "project," "should," "would" and similar expressions
may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking
statements include, but are not limited to, the impact of recent financial and operational achievements on future quarterly performance,
potential future financings, and the anticipated regulatory progress of stenoparib following the final outcome of our Phase 2 clinical
trial. Any forward-looking statements in this press release are based on management's current expectations of future events and
are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth
in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to the risks associated with
maintaining compliance with Nasdaq's continued listing requirements, obtaining regulatory approval for stenoparib, and potential market
fluctuations that could impact our financial stability and the drug's market entry. For a discussion of other risks and uncertainties,
and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements,
see the section entitled "Risk Factors" in our Form S-1 registration statement filed on April 17, 2024, and our Form 10-K
annual report on file with the Securities and Exchange Commission (the "SEC"), available at the SEC's website at www.sec.gov,
and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with
the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information
unless required by law.
Allarity Therapeutics, Inc. | 24
School Street, 2nd Floor | Boston, MA | U.S.A. | NASDAQ:
ALLR | www.allarity.com
ALLARITY THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands, except for share
| March 31, | December 31, | |||||||
| 2024 | 2023 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash | $ | 312 | $ | 166 | ||||
| Other current assets | 110 | 209 | ||||||
| Prepaid expenses | 542 | 781 | ||||||
| Tax credit receivable | 1,331 | 815 | ||||||
| Total current assets | 2,295 | 1,971 | ||||||
| Non-current assets: | ||||||||
| Property, plant and equipment, net | 18 | 20 | ||||||
| Intangible assets | 9,656 | 9,871 | ||||||
| Total assets | $ | 11,969 | $ | 11,862 | ||||
| LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 11,058 | $ | 8,416 | ||||
| Accrued liabilities | 1,553 | 1,309 | ||||||
| Warrant derivative liability | 2,664 | 3,083 | ||||||
| Income taxes payable | 43 | 59 | ||||||
| Convertible promissory notes and accrued interest, net of debt discount | 2,690 | 1,300 | ||||||
| Total current liabilities | 18,008 | 14,167 | ||||||
| Non-current liabilities: | ||||||||
| Deferred tax | 432 | 446 | ||||||
| Total liabilities | 18,440 | 14,613 | ||||||
| Commitments and contingencies (Note 16) | ||||||||
| Stockholders' (deficit) equity | ||||||||
| Series A Preferred stock $0.0001 par value (20,000 shares designated) shares issued and outstanding at March 31, 2024 and December 31, 2023 were 1,215 and 1,417, respectively (liquidation preference of $4.36 at March 31, 2024) | 1,510 | 1,742 | ||||||
| Common stock, $0.0001 par value (750,000,000 shares authorized, at March 31, 2024 and December 31, 2023); shares issued and outstanding at March 31, 2024 and December 31, 2023 were 342,774 and 294,347, respectively | - | - | ||||||
| Additional paid-in capital | 90,699 | 90,369 | ||||||
| Accumulated other comprehensive loss | (386 | ) | (411 | ) | ||||
| Accumulated deficit | (98,294 | ) | (94,451 | ) | ||||
| Total stockholders' deficit | (6,471 | ) | (2,751 | ) | ||||
| Total liabilities, preferred stock and stockholders' (deficit) equity | $ | 11,969 | $ | 11,862 |
common share data has been retroactively adjusted to effect the reverse stock split in 2024.
Allarity Therapeutics, Inc. | 24
School Street, 2nd Floor | Boston, MA | U.S.A. | NASDAQ:
ALLR | www.allarity.com
ALLARITY THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS
(U.S. dollars in thousands, except for share
| Three months ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 2,170 | $ | 1,427 | ||||
| General and administrative | 2,070 | 2,241 | ||||||
| Total operating expenses | 4,240 | 3,668 | ||||||
| Loss from operations | (4,240 | ) | (3,668 | ) | ||||
| Other income (expenses) | ||||||||
| Interest income | - | 4 | ||||||
| Interest expense | (102 | ) | (92 | ) | ||||
| Foreign exchange gains | 76 | 95 | ||||||
| Change in fair value adjustment of derivative and warrant liabilities | 419 | 309 | ||||||
| Net other income | 393 | 316 | ||||||
| Net loss for the period before tax benefit | (3,847 | ) | (3,352 | ) | ||||
| Income tax benefit | 4 | - | ||||||
| Net loss | (3,843 | ) | (3,352 | ) | ||||
| Deemed dividend of 5% on Series C Convertible Preferred stock | - | (4 | ) | |||||
| Gain on extinguishment of Series A Convertible Preferred stock | 191 | - | ||||||
| Deemed dividend on Series A Convertible Preferred stock | (228 | ) | - | |||||
| Net loss attributable to common stockholders | $ | (3,880 | ) | $ | (3,356 | ) | ||
| Basic and diluted net loss per common stock | $ | (22.14 | ) | $ | (6,356.06 | ) | ||
| Weighted-average number of common stock outstanding, basic and diluted | 175,266 | 528 | ||||||
| Other comprehensive loss, net of tax: | ||||||||
| Net loss | $ | (3,843 | ) | $ | (3,352 | ) | ||
| Change in cumulative translation adjustment | 25 | 84 | ||||||
| Total comprehensive loss attributable to common stockholders | $ | (3,818 | ) | $ | (3,268 | ) |